Online Webinars

Previous Webinars

Oct 9, 2018

Identifying Spatial Expression Patterns in the Tumor Microenvironment

Summary: In this webinar, Dr. Rognoni describes the development of an automated workflow for quantitative analysis of multispectral immunofluorescence whole-tissue scans. This technique, developed at Definiens, allows the identification of spatial patterns for immunoprofiling, overcoming the limitation of small regions of interests and providing significant amount of data on the...
View Full Event Post
Sep 12, 2018

Tissue-based profiling for confident decisions in immuno-oncology

Summary This webcast highlights the benefits of standardizing tissue profiling for decision making in drug development and trial designs in immuno-oncology. Key topics include: Challenges in comparing results across different clinical studies that result from inconsistent biomarker strategies are discussed A harmonized tissue profiling strategy is introduced as a promising...
View Full Event Post
Jul 26, 2018

Deep Learning: Automated PD-L1 Tumor Cell Scoring of Resected NSCLC

PD-L1 expression measured by immunohistochemistry helps identify non-small cell lung cancer (NSCLC) patients that may respond to anti-PD-1/PD-L1 immunotherapies. In this webinar, our featured speaker will present a novel deep learning solution for the automated scoring of PD-L1+ tumor cells (TC) in whole slide images of resected NSCLC. A convolutional...
View Full Event Post
Nov 21, 2017

Multiplex IHC Immuno-Oncology Panel

Characterization of the immune status of patients becomes increasingly important to personalize cancer treatments. The required extraction of information and biological insights from tissue slides remains challenging because of the broad heterogeneity of tumor and immune cells embedded in the complex tumor microenvironment. Thus, the analysis requires expert insights as...
View Full Event Post
Jun 26, 2017

Imaging-based subtypes of pancreatic cancer

The outcomes of pancreatic cancer have seen little improvement over the past three decades. The disease is associated with a poor prognosis and lack of response to chemotherapy and radiation. To date, there are no reliable ways to separate patients into prognostic groups based on the cancer biology, which would...
View Full Event Post